论文部分内容阅读
Traditionally, stent thrombosis has been regarded as a complication of percutaneous coronary interventions during the first 30 postprocedural days. However, delayed endothelialization associated with the implantation of drug-eluting stents may extend the risk of thrombosis beyond 30 days. Data are limited regarding the risks and the impact of this phenomenon outside clinical trials. Abstract: To evaluate the incidence, predictors, and clinical outcome of stent thrombosis after implantation of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Design, Setting, and Patients: Prospective observational cohort study conducted at 1 academic hospital and 2 community hospitals in Germany and Italy. A total of 2229 consecutive patients underwent successful implantation of sirolimus-eluting(1062 patients, 1996 lesions, 2272 stents) or paclitaxel-eluting(1167 patients, 1801 lesions, 2223 stents) stents between April 2002 and January 2004. Interventions: Implantation of a drug-eluting stent(sirolimus or paclitaxel). All patients were pretreated with ticlopidine or clopidogrel and aspirin. Aspirin was continued indefinitely and clopidogrel or ticlopidine for at least 3 months after sirolimus-eluting and for at least 6 months after paclitaxeleluting stent implantation. Main Outcome Measures: Subacute thrombosis(from procedure end through 30 days), late thrombosis( >30 days), and cumulative stent thrombosis. Results: At 9- month follow-up, 29 patients(1.3% ) had stent thrombosis(9[0.8% ] with sirolimus and 20[1.7% ] with paclitaxel; P=.09). Fourteen patients had subacute thrombosis(0.6% ) and 15 patients had late thrombosis(0.7% ). Among these 29 patients, 13 died(case fatality rate, 45% ). Independent predictors of stent thrombosis were premature antiplatelet therapy discontinuation(hazard ratio[HR], 89.78; 95% CI, 29.90- 269.60; P< .001), renal failure(HR, 6.49; 95% CI, 2.60- 16.15; P< .001), bifurcation lesions(HR, 6.42; 95% CI, 2.93- 14.07; P< .001), diabetes(HR, 3.71; 95% CI, 1.74- 7.89; P=.001), and a lower ejection fraction(HR, 1.09; 95% CI, 1.05- 1.36; P< .001 for each 10% decrease). Conclusions: The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive “ real-world” patients was substantially higher than the rate reported in clinical trials. Premature antiplatelet therapy discontinuation, renal failure, bifurcation lesions, diabetes, and low ejection fraction were identified as predictors of thrombotic events.
Traditionally, stent thrombosis has been considered as a complication of percutaneous coronary interventions during the first 30 postprocedural days. However, delayed endothelialization associated with the implantation of drug-eluting stents may extend the risk of thrombosis beyond 30 days. Data are limited regarding the risks and the impact of this phenomenon outside clinical trials. Abstract: To evaluate the incidence, predictors, and clinical outcome of stent thrombosis after implantation of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Design, Setting, and Patients: Prospective observational cohort study conducted at 1 academic hospital and 2 community hospitals in Germany and Italy. A total of 2229 consecutive patients underwent successful implantation of sirolimus-eluting (1062 patients, 1996 lesions, 2272 stents) or paclitaxel-eluting (1167 patients, 1801 lesions, 2223 stents) stents between April 2002 and January 2004. Interventions: Implantation of All patients were pretreated with ticlopidine or clopidogrel and aspirin. Aspirin was continued indefinitely and clopidogrel or ticlopidine for at least 3 months after sirolimus-eluting and for at least 6 months after paclitaxeleluting stent implantation. Main Outcome Measures: Subacute thrombosis (from procedure end through 30 days), late thrombosis (> 30 days), and cumulative stent thrombosis. Results: At 9- month follow-up, 29 patients (1.3%) had stent thrombosis Fourteen patients had subacute thrombosis (0.6%) and 15 patients had late thrombosis (0.7%). Among these 29 patients, 13 died (case fatality [0.8%] with sirolimus and 20 [1.7%] with paclitaxel; 95% CI, 29.90-269.60; P <.001), renal failure (HR, 6.49; 95% CI, 2.60-16.15; P <.001), bifurcation lesions (HR, 6.42; 95% CI, 2.93-14.07; P <.001),(HR, 3.71; 95% CI, 1.74-7.89; P = .001), and a lower ejection fraction (HR, 1.09; 95% CI, 1.05-1.36; P <.001 for each 10% decrease) : The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive “real-world” patients was substantially higher than the rate reported in clinical trials. Premature antiplatelet therapy discontinuation, renal failure, bifurcation lesions, diabetes, and low ejection fraction were identified as predictors of thrombotic events.